AURINIA PHARMACEUTICALS ($AUPH) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $0.26 per share, beating estimates of $0.22 by $0.04. The company also reported revenue of $77,110,000, beating estimates of $76,342,236 by $767,764.
You can see Quiver Quantitative's $AUPH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AURINIA PHARMACEUTICALS Hedge Fund Activity
We have seen 130 institutional investors add shares of AURINIA PHARMACEUTICALS stock to their portfolio, and 123 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 1,629,600 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,007,080
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 873,662 shares (-99.9%) from their portfolio in Q4 2025, for an estimated $13,934,908
- NOMURA HOLDINGS INC added 839,939 shares (+265.6%) to their portfolio in Q4 2025, for an estimated $13,397,027
- TWO SIGMA ADVISERS, LP added 825,900 shares (+172.1%) to their portfolio in Q4 2025, for an estimated $13,173,105
- MAN GROUP PLC added 670,812 shares (+368.9%) to their portfolio in Q4 2025, for an estimated $10,699,451
- READYSTATE ASSET MANAGEMENT LP removed 657,835 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,269,076
- LSV ASSET MANAGEMENT added 656,847 shares (+inf%) to their portfolio in Q4 2025, for an estimated $10,476,709
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AURINIA PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AUPH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for AURINIA PHARMACEUTICALS, check out Quiver Quantitative's $AUPH forecast page.
AURINIA PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AUPH recently. We have seen 3 analysts offer price targets for $AUPH in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Joseph Schwartz from Leerink Partners set a target price of $16.0 on 12/03/2025
- Maury Raycroft from Jefferies set a target price of $21.0 on 11/07/2025
- Douglas Miehm from RBC Capital set a target price of $15.0 on 11/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
